Caroline Seymour

Biond Biologics Ltd. will join Sanofi in an exclusive worldwide license agreement for the development and commercialization of the novel immunotherapy BND-22.

Shella Saint Fleur-Lominy, MD, PhD, discusses the current landscape of MPNs and the importance of addressing disease burden and progression.

Marc J. Braunstein, MD, PhD, discusses the current landscape of newly diagnosed multiple myeloma and the utility of minimal residual disease in the research sphere.

Lecia V. Sequist, MD, discusses some of the biggest advancements of 2020 in lung cancer.

January 29, 2021 - The HER3-directed antibody-drug conjugate patritumab deruxtecan continued to demonstrate clinically meaningful antitumor activity and a manageable safety profile at the recommended expansion dose of 5.6 mg/kg in pretreated patients with metastatic or unresectable EGFR-mutant non–small cell lung cancer.

January 28, 2021 - Rapid, high, and uniform brain exposure was seen with [11C]osimertinib, followed by a reduction in total brain metastases volume with oral administration of the EGFR TKI in patients with EGFR-mutant non–small cell lung cancer and brain metastases.

During the question-and-answer portion of the virtual Institutional Perspectives in Cancer webinar, Earle Burgess, MD, and colleagues provide insight into how they are navigating the evolving treatment landscape of renal cell carcinoma and bladder cancer.

David Spigel, MD, discusses the future of adjuvant targeted therapy in lung cancer.

The sustained overall survival benefit with durvalumab and significant disease-free survival benefit benefit with osimertinib in the adjuvant setting represent major advances in the field of non–small cell lung cancer, fueling research with each modality in localized settings.

David Spigel, MD, discusses ongoing research with immunotherapy in early-stage lung cancer.

Andrew Spencer, MD, MBBS, FRACP, FRCPA discusses the significance of the PANORAMA 3 study in multiple myeloma.

Alison R. Sehgal, MD, discusses some of the novel approaches that have been adopted into practice and ongoing research building on the advances that have been made with targeted therapy.

Despite the availability of next-generation PET imaging modalities that can detect metastasis earlier, apalutamide, enzalutamide, and darolutamide remain the standard of care for patients with nonmetastatic castration-resistant prostate cancer who have a prostate-specific antigen doubling time of less than 10 months.

January 17, 2021 - The combination of atezolizumab and bevacizumab continued to display improved survival compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma.

Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.

Lecia V. Sequist, MD, MPH, discusses some of the advances that bore out in 2020 in HER2-mutant lung cancer and previewed anticipated developments in 2021.

January 13, 2021 - Defining treatment goals for patients with myeloproliferative neoplasms is critical in order to optimize therapy, even if the dominant concern is disease progression.

Yanyan Lou, MD, PhD, highlighted the role of atezolizumab, durvalumab, pembrolizumab, and nivolumab and how they have demonstrated improved survival in combination with etoposide and platinum in untreated extensive-stage small cell lung cancer, cementing checkpoint inhibition plus chemotherapy as a frontline standard.

Germline predisposition variants associated with cancer susceptibility syndromes can underlie the genetic risk for rhabdomyosarcoma, indicating that germline testing should be performed in accordance with RMS subtypes and irrespective of age.

Clinical risk continues to guide treatment decisions in early-stage HER2-positive breast cancer. The presence of brain metastases has become a driving force for treatment selection in the metastatic setting.

Phuong L. Mai, MD, discusses the situations in which genetic testing should be considered and the importance of bridging awareness and access within oncology.

Balazs Halmos, MD, discussed differences in the management of early- vs late-stage non–small cell lung cancer and the erasure of single-modality therapy across the field.

Stephen Liu, MD, discusses some pivotal data that support the expanding reach of targeted therapy in non–small cell lung cancer.

Matthew P. Goetz, MD, discusses ongoing research in the setting of ESR1-mutant, ER–positive, HER2-negative metastatic breast cancer.

December 17, 2020 - Merck is set to build a new manufacturing facility to increase its production of TICE Bacillus Calmette–Guérin, tripling its current manufacturing capacity.

Checkpoint inhibitors have failed to improve progression-free survival and overall survival as second-line therapy and maintenance therapy in small cell lung cancer, but this class of agents continue to show encouraging activity worthy of a paradigm shift up front.

The clinical tool RSClin™, which integrates the 21-gene expression assay and clinical pathologic features, was shown to provide more prognostic information than the 21-gene recurrence score or clinical pathologic features alone and a more precise prediction of absolute chemotherapy benefit in node-negative early breast cancer.

December 10, 2020 — The combination of ipatasertib and paclitaxel failed to show a significant improvement in progression-free survival vs placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered locally advanced, unresectable or metastatic triple-negative breast cancer.

The combination of alpelisib and letrozole sustained efficacy and did not result in any new safety signals in patients with PIK3CA-mutant hormone receptor–positive, HER2-negative advanced breast cancer who received prior treatment with the combination of a CDK4/6 inhibitor and fulvestrant.

The addition of chemotherapy to endocrine therapy led to an improvement in 5-year invasive disease-free survival and overall survival in premenopausal but not postmenopausal women with hormone receptor–positive, HER2-negative, lymph node–positive breast cancer and a recurrence score between 0 and 25.